MDA 2023 poster: Ataluren preserves muscle burst activity in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial
This poster, presented at MDA 2023, provides an overview of a phase 3 trial assessing the effects of ataluren on muscle burst activity in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Learn about the baseline demographics of patients with nmDMD in both study groups
Discover ataluren efficacy outcomes on muscle burst activity in the intention-to-treat (ITT) population
Explore ataluren safety results in the ITT population
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster was developed and funded by PTC Therapeutics for MDA 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300065 | May 2023
Sign in or register to access exclusive content on this site